Strides Arcolab partners with Gilead to produce and distribute Hepatitis C drug

Strides Arcolab has partnered with Gilead Sciences Inc whereby the latter has licensed Strides to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic Hepatitis C, for distribution to 91 developing countries including India, Eqypt & Indonesia which are high burden countries. The pharma major is one among 7 companies in India who are licensed by Gilead Sciences Inc.

The countries within the agreement account for more than 100 million people living with Hepatitis C globally representing 54% of the total globally infected population.

Under this licensing agreement, Strides receives a complete technology transfer of the Gilead manufacturing process for both API & finished product to enable scale up production as quickly as possible. Strides can also set its own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other business essential activities. The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic Hepatitis C medicines.